Avalglucosidase alfa
Contents
Description
Avalglucosidase alfa is a next-generation enzyme replacement therapy for Pompe disease (acid alpha-glucosidase deficiency). It is designed with enhanced uptake into target tissues via mannose-6-phosphate receptors. Clinical trials demonstrated superior respiratory and motor function improvements compared to the previous standard alglucosidase alfa, particularly in late-onset Pompe disease patients.
Indications & Therapeutic Use
Pompe disease (acid alpha-glucosidase deficiency) in adults and pediatric patients
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Avalglucosidase alfa — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Avalglucosidase alfa products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | avalglucosidase alfa |
| Brands | 1 brand available |
| Active Ingredient | avalglucosidase alfa-ngpt |
| Drug Class | Pompe disease (acid alpha-glucosidase deficiency) in adults and pediatric patients |
| Manufacturer | Sanofi Genzyme |
| Dosage Forms | Intravenous infusion, 100mg lyophilized powder |
| Medical Code | A16AB13 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved (2021), EMA Approved (2021) |
| Clinical Trial | NCT02782741 |
| Countries | 7 countries |